← Leaderboards
Julia F Charles
Brigham And Women'S Hospital
$3,442,362
Attributed
$4,327,307
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $718.8K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,327,307 · 6
By mechanism
R01$2,848,846 · 3
R21$859,925 · 2
K08$618,536 · 1
Top collaborators
- Thomas Levin Geiser Andersen5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Bruce D Levy$29,805,980
- Antonios O Aliprantis$2,553,286
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelBoneOsteoclastsSkeletalOsteoblastsCellsOsteoporosisIn VivoAffectBone ResorptionInnovationMediatingBone LossTnfsf11 GeneMolecularBone RemodelingPhenotypeIn VitroBone MarrowCell TypeOsteogenesisCytokineInsightMutation
Grant awards (21)
Mechanisms of bone fragility in Autosomal Dominant Osteopetrosis type II: from human to mouse and back$283,386
R01 · FY2025 · AR · contact PI
Osteoclasts or RANKL: Which is the critical target in treatment of fibrous dysplasia bone lesions?$174,545
R21 · FY2025 · AR · contact PI
Mechanisms of bone fragility in Autosomal Dominant Osteopetrosis type II: from human to mouse and back$127,550
R01 · FY2025 · AR · contact PI
Mechanisms of bone fragility in Autosomal Dominant Osteopetrosis type II: from human to mouse and back$412,092
R01 · FY2024 · AR · contact PI
Osteoclasts or RANKL: Which is the critical target in treatment of fibrous dysplasia bone lesions?$228,972
R21 · FY2024 · AR · contact PI
Mechanisms of bone fragility in Autosomal Dominant Osteopetrosis type II: from human to mouse and back$452,041
R01 · FY2023 · AR · contact PI
Mechanisms of bone fragility in Autosomal Dominant Osteopetrosis type II: from human to mouse and back$494,822
R01 · FY2022 · AR · contact PI
Talking Back: leveraging dysfunctional osteoclasts to identify novel pathways of osteoclast-osteoblast communication$192,832
R21 · FY2022 · AR · contact PI
Diversity Supplement: Talking Back: Leveraging dysfunctional osteoclasts to identify novel pathways of osteoclast-osteoblast communication$31,120
R21 · FY2022 · AR · contact PI
Talking Back: leveraging dysfunctional osteoclasts to identify novel pathways of osteoclast-osteoblast communication$232,456
R21 · FY2021 · AR · contact PI
Myeloid precursors and the microbiome in the osteoimmunology of aging$204,825
R01 · FY2017 · AG · contact PI
Myeloid precursors and the microbiome in the osteoimmunology of aging$204,825
R01 · FY2016 · AG · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$90,691
K08 · FY2016 · AR · contact PI
Myeloid precursors and the microbiome in the osteoimmunology of aging$88,750
R01 · FY2016 · AG · contact PI
Regulation of osteoclast biology by anion exchanger SLC4A2 in mouse and human sys$382,000
R01 · FY2015 · AR · contact PI
Myeloid precursors and the microbiome in the osteoimmunology of aging$198,555
R01 · FY2015 · AG · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$131,814
K08 · FY2015 · AR · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$589
K08 · FY2015 · AR · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$131,814
K08 · FY2014 · AR · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$131,814
K08 · FY2013 · AR · contact PI
Osteoclast precursors in bone homeostasis and inflammatory arthritis$131,814
K08 · FY2012 · AR · contact PI